LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...

AstraZeneca has put a £450m investment in Britain under review in a stand-off with ministers over state aid. The drugs giant ...

AstraZeneca said it is in China ‘for the long haul’ and outlined billions of pounds of investment in the US – but a new ...

AstraZeneca, the London-listed pharmaceutical company, has put its planned £650 million investment in UK vaccine research and ...

AstraZeneca's £450 million investment plan for vaccine R&D in the UK is under review as discussions on governmental ...

London-listed drugmaker AstraZeneca said its plan to invest 650 million pounds ($833.2 million) in Britain for vaccine ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...

A Covid vaccine compensation scheme could be set up after thousands claimed they have been left disabled as a result of the AstraZeneca jab, The Telegraph has learnt ...

Accepting the accolade, Modi highlighted the importance of collaboration between nations to tackle global challenges like ...

The diplomatic row that broke out last week over the supply of AstraZeneca’s vaccine to Europe appears to have cooled after the UK pharma agreed to supply an extra nine million doses.

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.